# A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients

> **NCT00996476** · PHASE2 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 92 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** TMC435
- **DRUG:** PegIFNα-2a
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT00996476
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2014-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00996476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00996476, "A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00996476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*